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The active ingredient of ecstasy, ±3,4-methylenedioxymethamphetamine (MDMA), in
addition to its initial reinforcing effects, induces selective and non-selective brain
damage. Evidences suggest that the hippocampus (HC), a central region for cognition,
may be especially vulnerable to impairments on the long-run, nevertheless, transcription
factors that may precede and regulate such chronic changes remained uninvestigated
in this region. In the current study, we used gene-set enrichment analysis (GSEA) to
reveal possible transcription factor candidates responsible for enhanced vulnerability of
HC after MDMA administration. Dark Agouti rats were intraperitoneally injected with
saline or 15 mg/kg MDMA. Three weeks later HC gene expression was measured
by Illumina whole-genome beadarrays and GSEA was performed with MSigDB
transcription factor sets. The number of significantly altered genes on the genome level
(significance < 0.001) in up/downregulated sets was also counted. MDMA upregulated
one, and downregulated 13 gene sets in the HC of rats, compared to controls,
including Pax4, Pitx2, FoxJ2, FoxO1, Oct1, Sp3, AP3, FoxO4, and vitamin D receptor
(VDR)-regulated sets (q-value <0.05). VDR-regulated set contained the second highest
number of significantly altered genes, including among others, Camk2n2, Gria3, and
Grin2a. Most identified transcription factors are implicated in the response to ischemia
confirming that serious hypoxia/ischemia occurs in the HC after MDMA administration,
which may contribute to the selective vulnerability of this brain region. Moreover, our
results also raise the possibility that vitamin D supplementation, in addition to the
commonly used antioxidants, could be a potential alternative method to attenuate
MDMA-induced chronic hippocampal impairments.
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INTRODUCTION
Ecstasy is a commonly abused drug worldwide for its stimulating, pro-social and euphoric effects
(Green et al., 2003). The active ingredient of ecstasy is 3,4-methylenedioximethamphetamine
(MDMA) that acutely releases noradrenaline, serotonin, and dopamine in synaptic clefts (Green
et al., 2003; Pazmany et al., 2013). Besides of its initial rewarding effects, the drug can lead
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to lasting functional consequences: elevated risk of mood
disorders and persistent cognitive disturbances were
demonstrated in multiple animal and human studies (Parrott
et al., 2000; Green et al., 2003; Bond et al., 2004; Kalechstein et al.,
2007; Nulsen et al., 2010). A central region of cognitive functions,
particularly memory, is the hippocampus (HC) (Sweatt, 2004).
Its anatomical structure, in terms of organization of neuronal
circuitries and (micro)vasculature makes it especially vulnerable
to various homeostatic challenges (Schmidt-Kastner and Freund,
1991). The HC seems to be the most vulnerable brain region
also to the toxic effects of MDMA in rats and, with some
suggestive evidence, in humans (Adori et al., 2006, 2010; den
Hollander et al., 2012; Petschner et al., 2018). MDMA-induced
hyperthermia, free radical production, relative ischemia through
disruption of cerebral autoregulation (Colado et al., 1999; Green
et al., 2003; Ferrington et al., 2006; Capela et al., 2009) and
lasting selective serotonergic toxicity (Kirilly et al., 2006; Capela
et al., 2009; Adori et al., 2010, 2011b; Ando et al., 2010) are
all mechanisms that could contribute to the damage of HC.
Translation of these complex pathophysiological processes to
molecular mechanisms leading to the damage of the HC and to
impairments of learning and memory processes are, however,
less explored, although changes in LTP in hippocampal slices
after neurotoxic MDMA treatment have been described earlier
(Morini et al., 2011). We have demonstrated previously that
mRNA levels of key members of the long-term potentiation
(LTP) pathway were downregulated in the HC 3-weeks after
MDMA administration, in parallel with decreased expression
of memory and cognition gene sets (Petschner et al., 2018).
These may be important contributors to MDMA-induced
cognitive impairments. However, based on the complexity of
the pathophysiological processes mentioned above, further
molecular mechanisms are presumed to contribute. These
probably employ downstream mediators, like transcription
factors, which regulate expression of mRNA and protein levels
directly, and link initial alterations with long-term consequences.
Nevertheless, transcription factors remained uninvestigated after
chronic MDMA administration.
In the present study, we have analyzed our previously
obtained data, measured by Illumina whole-genome beadarrays,
with gene-set enrichment analysis (GSEA) using the MSigDB
transcription factor sets, to identify transcription factors that
may be responsible for the long-term cognitive impairments in
the vulnerable HC region 3-weeks after a single-dose MDMA
administration.
MATERIALS AND METHODS
For detailed methods see (Petschner et al., 2018). Briefly, 21
approximately 8 weeks old male Dark Agouti (DA) rats (Harlan,
Olac Ltd., Shaw’s Farm, Blackthorn, Bicester, United Kingdom)
weighing 152 ± 3,58 g (SEM) were used. After random
assignment, MDMA [(±)3,4-methylenedioxymethamphetamine
(Sanofi-Synthelabo-Chinoin, Hungary, purity >99.5%)]
dissolved in 0.9% NaCl (SAL), at an equivalent dose of 15 mg/kg
free base, or SAL (for control animals) was administered
intraperitoneally in a volume of 1 ml/kg. Three weeks after
injections rats were sacrificed and HC regions dissected (dorsal
HC: from bregma −2.5 to −4.5 mm). RNA extraction was
performed according to the TRIzol method (Tamasi et al., 2014;
Petschner et al., 2016). Samples with lowest RNA concentrations
were excluded until both MDMA and control groups consisted
of eight animals. Randomly selected samples were pooled by
two and sent to Service XS (Leiden, Netherlands) for microarray
analysis with the Illumina (San Diego, CA, United States)
RatRef-12v1 beadarray expression chip. Raw data were analyzed
using quantile normalization with beadarray, preprocessCore
and puma Bioconductor packages for R (Gentleman et al., 2004;
Dunning et al., 2007; Pearson et al., 2009; R Core Team, 2012).
These methods created the minimum probability of positive
log ratio (MinPplr), a statistical significance value. A gene was
considered significant, if MinPplr was below 0.001 [to correct
for multiple hypothesis testing (Benjamini and Hochberg, 1995;
Petschner et al., 2015)]. Results were validated with rt-PCR (for
result see Petschner et al., 2018) and microarray data uploaded in
Gene Expression Omnibus (Edgar et al., 2002) under GSE475411.
GSEA was performed using GSEA software from the Broad
Institute at MIT2. GSEA uses a ranked list of all examined genes
and searches for groups of genes (gene sets) that are enriched
(overrepresented/underrepresented) in the top/bottom of this
list. We used official MSigDB C3 TFT (transcription factor)
gene sets for grouping, which classifies genes based on shared
regulatory motifs and, hence, represents common transcription
factor binding properties. Accordingly, up/downregulation of a
given set in GSEA means that genes regulated by a given factor
are up/downregulated. Sets containing more than 500/less than
15 genes were excluded, t-test was used for ranking and gene
set was chosen as permutation type. Thousand permutations
were made with seed of permutation set to 149. Normalized
enrichment scores (NES), representing relative enrichment in
a given phenotype, nominal p-values and false discovery rates
(FDR) were calculated. A gene set was considered significant
with FDR q-value below 0.05 (Benjamini and Hochberg, 1995).
GSEA calculates results obtained through analysis of every
(both significant/non-significant) genes between two groups (in
this case MDMA vs. SAL). However, we were also interested
in sets that may contain most of the significantly altered
genes. Therefore, the number of significantly altered genes
(MinPplr < 0.001) was counted in each significant (FDR < 0.05)
gene set to identify those transcription factors that may be largest
contributors to the most substantial changes in the HC 3 weeks
after administration.
All experiments complied with the European Community
Council Directive of 24 November 1986 (86/609/EEC), National
Institutes of Health Principles of Laboratory Animal Care
(NIH Publication 85-23, revised 1985) and national laws (the
Hungarian Governmental Regulation on animal studies, 31
December 1998 Act) and were approved by the National Scientific
Ethical Committee on Animal Experimentation and permitted
by the Food Chain Safety and Animal Health Directorate of
1http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47541
2http://www.broadinstitute.org/gsea
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the Central Agricultural Office, Hungary (permission number:
22.1/3152/001/2007).
RESULTS
Gene-set enrichment analysis revealed 14 gene sets that were
dysregulated with an FDR q-value below 0.05 3 weeks after
a single-dose MDMA treatment in the HC compared to the
controls (Table 1). Among the gene sets one was upregulated,
the other 13 were downregulated with the largest downregulation
of the Pax4 set (the only upregulated set possesses no known
binding factor). From the 14 dysregulated gene sets three bind
forkhead box (Fox) transcription factors, namely FoxO1, FoxO4,
and FoxJ1, others could not be grouped into families.
To reveal gene sets with the highest number of altered genes,
we counted significant gene entries (MinPplr < 0.001) in each
significant set (FDR < 0.05). Results showed that AP3 regulated
gene set contained the most significantly altered genes with
17 entries, [but AP3 is currently not associated with known
transcription factor (see section “Discussion”)], followed by
vitamin D receptor (VDR) regulated set with 15 entries. Results
with the significant genes are shown in Table 2.
DISCUSSION
The present study shows that gene expression alterations 3 weeks
after a single-dose MDMA treatment in the HC are probably
mediated by 14 different transcription factors, among them
hypoxia/ischemia-induced members of the FoxO family, Sp3 and
Pax4. The AP3 regulated set contained the most significantly
dysregulated genes, but lacks associated transcription factor,
while the VDR gene set contained the second most entries.
These results suggest that etiologically hypoxia/ischemia may be
an important factor in the vulnerability of the HC and vitamin
D supplementation may be tested to compensate for the most
substantial cognitive effects of the drug.
Among transcription factors regulating the significantly
altered sets several could be related to hypoxia/ischemia, a known
consequence of MDMA administration (Ferrington et al., 2006).
For example, the Pax4 regulated gene set was downregulated
after transient hypoxic condition in the fetal pituitary of sheep
(Wood et al., 2016). FoxO1 and FoxO4 were implicated in
antioxidant mechanisms after brain ischemia (Abbas et al., 2009;
Fukunaga and Shioda, 2009; Araujo et al., 2011; Jenwitheesuk
et al., 2017). Polymorphisms in Pitx2 associated consistently
with ischemic stroke in genome-wide association studies [Traylor
et al., 2012; Malik et al., 2016; Ninds Stroke Genetics Network
(SiGN) and International Stroke Genetics Consortium (Isgc),
2016]. Significantly decreased Sp3 protein levels were revealed
after 7 days of hypobaric hypoxia in HC of rats (Hota et al.,
2010). Other transcription factors had wide-scale roles in
different processes, e.g., FoxJ2 is an important regulator of
dopaminergic neurons (Wijchers et al., 2006) and Oct1 (Pou2f1)
polymorphisms associated with Alzheimer’s disease (Taguchi
et al., 2005). Core-binding factor is a large complex from
Runx1-3 and core-binding factor B, which possesses important
transcriptional regulatory properties, and Runx1 was induced
after traumatic brain injury (Logan et al., 2013). From the
dysregulated gene sets in four, including the only upregulated
one, genes are annotated only by common regulatory motifs that
are not associated with known transcription factors, indicating
that so far unidentified regulatory elements may also contribute
to the long-term effects of MDMA. In sum, our results suggest
that MDMA employs FoxO1/4, Pitx2, Sp3, and Pax4-dependent
TABLE 1 | Up- and downregulated transcription factor gene sets 3 weeks after a single-dose MDMA treatment in the hippocampus of Dark Agouti rats.
Name of the gene set Presumed transcription
factor able to bind to
regulatory motif
NES FDR q-value
ACTWSNACTNY_UNKNOWN Unknown 1.936839 0.022079093
V$VDR_Q6 Vitamin D receptor −1.7801763 0.047251813
AACWWCAANK_UNKNOWN Unknown −1.8135455 0.03694073
V$FOXO4_01 FoxO4 −1.8182034 0.038588446
GTGGGTGK_UNKNOWN Unknown −1.8234655 0.039833214
V$AP3_Q6 Currently unknown −1.8274099 0.042258345
V$SP3_Q3 Sp3 −1.8449765 0.03698938
V$COREBINDINGFACTOR_Q6 Core−binding factor −1.8531265 0.038751207
V$OCT1_03 Oct1 (Pou2f1) −1.8553681 0.04364336
V$FOXO1_01 FoxO1 −1.8712838 0.042675186
V$FOXJ2_02 FoxJ2 −1.8762817 0.049202178
YRCCAKNNGNCGC_UNKNOWN Unknown −1.9217957 0.037266485
V$PITX2_Q2 Pitx2 −1.9697808 0.025443465
V$PAX4_04 Pax4 −2.1240275 0.0034508866
According to the gene set enrichment analysis, altogether 14 gene sets were dysregulated (1 up- and 13 downregulated, marked with red and blue, respectively) with a
false discovery rate (FDR) below 0.05. All of the significant sets are shown here in descending order, according to their nominal enrichment scores (NES), thus, toward
lower expression of their respective genes. Table contains the most probable transcription factors that may bind regulatory motifs. Those genes, that were annotated to a
set based only on common regulatory motifs, but unknown transcription factors are marked as “unknown” in their respective columns (four sets). AP3 set currently lacks
associated transcription factor.
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mechanisms after its initial vasoactive monoamine release and
consequent ischemia/hypoxia and changes in these transcription
factors may be responsible for the long-lasting influence on HC
processes and the often observed cognitive impairments.
From this aspect, perhaps the most interesting result is
that most of the VDR regulated genes were downregulated
(see Table 2). In fact, the second highest number of genes
with significantly altered expressions were among the VDR
regulated genes, including those involved in LTP, like upregulated
calcium/calmodulin-dependent kinase inhibitor Camk2n2 and
downregulated glutamate receptors NMDA2A (Grin2a) and
AMPA3 (Gria3). While some of the other transcriptional
regulators may also influence genes important for regulation of
LTP, none of them offer such straightforward intervention as
VDR regulated one in the form of vitamin D supplementation.
This is especially tempting for multiple reasons. First, vitamin D
exerts its effects via VDR, which after activation binds directly
to DNA and influences gene transcription (Whitfield et al.,
1995; Haussler et al., 1997; Angelo et al., 2008). Vitamin D was
demonstrated to counteract consequences of hypoxia/ischemia
via VDR (Won et al., 2015), showed neuroprotective effects in
hippocampal neurons after hypoxic insult (Kajta et al., 2009),
could influence LTP (Salami et al., 2012), enhanced cognitive
performance in dementia (Landel et al., 2016), and protected
from the serotonin-depleting effects of methamphetamine, a
close relative of MDMA (Cass et al., 2006). Furthermore, a
transient decrease in plasma calcitriol level was demonstrated
in humans by a metabolomic analysis after acute MDMA
administration (Boxler et al., 2018) and ecstasy users promote the
use of vitamin D in user-to-user posts3. However, no previous
studies investigated vitamin D effects after MDMA use (in
PubMed no hit with “MDMA” and “vitamin D” MeSH terms,
retrieved on 11th of August, 2018). Harm-reduction techniques,
found overall on the internet, target known acute actions of
MDMA and suggest application of antioxidants, hydration, and
cooling to attenuate the negative effects. Among those cooling
was extensively studied and showed limited success (see e.g.,
Adori et al., 2011a). Nevertheless, based on our results, vitamin D
might have the potential to compensate for some of the long-term
consequences of MDMA in the highly vulnerable HC.
3 www.treato.com
CONCLUSION
While our study has to be interpreted with caution due
to the indirect examination of the transcription factors and
the exclusive investigation of the HC, it provides evidence
for an important role of ischemia and subsequent FoxO1/4,
Pitx2, Sp3, and Pax4-dependent mechanisms in MDMA-induced
hippocampal impairments. In addition, it also raises the
possibility of a better, simple, and precision-medicine based
harm reduction technique with vitamin D to compensate for the
cognitive deficits of the drug.
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